Home › Arthritis › NCT07284563
Ultralow Dose PET Imaging for 18F-NaF Uptake
Evaluation of Ultralow Dose PET Imaging for Detecting 18F-NaF Uptake
Who can join
Ages 18 to 120 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age ≥18 years. * Ability to provide informed consent and comply with study procedures. * For female participants: Must not be pregnant or breastfeeding; Negative pregnancy test required for women of childbearing potential. Exclusion Criteria: * Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 millisievert \[mSv\] total). * More than four prior enrollments in this study. * Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan * Medication \& Prior Treatment Exclusions * Concurrent treatments that may interfere with radiotracer uptake as determined by the Principle Investigator. * Pregnant or breastfeeding individuals (negative pregnancy test required) * Inability to provide informed consent * Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
About the study
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET imaging) technique for increased bone turnover that is found in diseases such as cancer, trauma, infection, arthritis, and other benign diseases of bone detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-sodium fluoride (NaF) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.
What is being tested
- 18F-NaF (drug)
Sponsor: Akiva Mintz · Participants: 200 · Started: Sep 1, 2025
Contact the study team
- Barbara Blanchfield · Phone: 973-255-4955
Official record on ClinicalTrials.gov — NCT07284563
Locations in the U.S.
| New Jersey | Nuclear Imaging Institute, Englewood |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.